Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Vasculitis

Vasculitis

Subtypes of Vasculitis

ANCA-Associated Vasculitis 9 Kawasaki disease 8 Microscopic Polyangiitis 5 Eosinophilic granulomatosis with polyangiitis 4 Giant cell arteritis 1

26 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Vasculitis

6 trials tracked for Vasculitis: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 136 citations.

6Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 2 Phase 2 2 Other / NA 2
  1. Phase 3 Belimumab in Remission of VASculitis Completed · 136 cited
  2. Phase 3 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Completed
  3. Phase 2 A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis Completed
  4. Phase 2 Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis Completed
  5. N/A Improving the Quality of Patient Care by Using a Clinical Expert System. Completed
  6. N/A PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Vasculitis: what the trials found

In patients with vasculitis, the use of rituximab in combination with cyclophosphamide was associated with a statistically significant achievement of disease remission compared to conventional therapy (p<0.001) 2.

While rituximab showed superior remission rates, there was no statistically significant difference between the rituximab and conventional therapy groups regarding the percentage of participants achieving a BVAS/WG score of 0 and successfully completing a glucocorticoid taper by 6 months post-randomization (p=0.133) 2.

Safety profiles were comparable between the rituximab and conventional therapy cohorts, with no statistically significant difference in the rate of selected adverse events (p=0.927) 2.

Recent results — preliminary, needs further review

  • A Phase 2 trial reported an 83% remission rate for patients treated with Rituximab, though this finding is not yet corroborated 4.

For the clinician treating this condition

  • Rituximab plus cyclophosphamide significantly improves disease remission rates compared to conventional therapy in vasculitis patients 2.
  • The addition of rituximab does not appear to significantly alter the rate of successful glucocorticoid tapering at 6 months compared to standard treatment 2.
  • Safety profiles for rituximab are comparable to conventional therapies regarding reported adverse events 2.

AI synthesis of 2 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review identifies shared immune mechanisms and therapeutic targets across cardiovascular inflammatory diseases
Rheumatology Sys. Review
Systematic review identifies shared immune mechanisms and therapeutic targets across cardiovascular inflammatory diseases Could one immune problem be driving three different heart conditions?
A systematic review examined shared immunological mechanisms across atherosclerosis, myocarditis, and vasculitis.
Three different heart diseases might share one immune trigger, suggesting new ways to treat plaque buildup, heart muscle inflammation, and b…
Frontiers Apr 8, 2026
Japanese AAV Cohort Shows MPA Has 67.6% Five-Year Survival; Glucocorticoid Reduction Not Linked to Better Outcomes
Infectious Disease Cohort
Japanese AAV Cohort Shows MPA Has 67.6% Five-Year Survival; Glucocorticoid Reduction Not Linked to Better Outcomes For Japanese patients with a rare autoimmune disease, survival remains challenging
A retrospective cohort study of 460 treatment-naïve Japanese patients with AAV found microscopic polyangiitis (MPA) had the poorest prognosi…
Japanese patients with microscopic polyangiitis face a five-year survival rate of 67.6%, as older age and kidney issues raise death risk.
Frontiers Apr 5, 2026